The phase 2 J-ALTA trial (NCT03410108), which evaluated the efficacy and safety of brigatinib in Japanese patients with ALK-positive NSCLC who were refractory to alectinib or other ALK TKIs, also included a cohort of patients who had not received any previous ALK TKI treatment [12]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.